At the news
? NEUTRALIMPACT 4/10 8-K filed Aug 20, 2026 at 07:04 ET
UroGen Pharma entered into an Option and Research License Agreement with IntraGel Therapeutics, securing an exclusive option for a worldwide license to develop and commercialize IntraGel's TumoCure product (using its SRGel sustained-release hydrogel platform) for advanced head and neck cancer, plus options for additional combination products. UroGen also agreed to invest up to $7,000,000 in IntraGel's equity. This is an early-stage, pre-clinical pipeline expansion into a new oncology indication with modest financial commitment, providing optionality without near-term revenue impact.
- UroGen obtained an exclusive option for a worldwide license to develop and commercialize IntraGel's TumoCure product for advanced head and neck cancer.
- UroGen also obtained options for exclusive worldwide licenses to develop additional products combining IntraGel's SRGel platform with compounds designated by UroGen.
- UroGen agreed to invest up to $7,000,000 in IntraGel's equity securities.
- The agreement was entered into on August 18, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access